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Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1
promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a
lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated
cell cycle markers, and inhibitors of Akt, NFjB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes
and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but
have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas
that arise spontaneously through age predisposition. These results suggest that Akt, NFjB, and Stat3 pathways may
serve as effective targets in the treatment of EBV-associated B cell lymphomas.
Citation: Shair KHY, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, et al. (2007) EBV latent membrane protein 1 activates Akt, NFjB, and Stat3 in B cell lymphomas. PLoS
Pathog 3(11): e166. doi:10.1371/journal.ppat.0030166
Introduction
Epstein-Barr virus (EBV) is a ubiquitous c-herpesvirus that
infects humans predominantly at an early age with greater
than 90% of the adult population infected with EBV [1]. EBV
is linked to the development of both B lymphocyte and
epithelial cell malignancies, including Burkitt lymphoma,
Hodgkin disease (HD), and nasopharyngeal carcinoma (NPC),
and cancers linked to immunosuppression, including post-
transplant lymphoma and AIDS-associated lymphomas [2,3].
In vitro infection of B lymphocytes with EBV induces
permanent growth transformation, and this ability to affect
cell growth regulation likely contributes to the development
of cancer.
Many of the viral proteins expressed in transformed cells,
including the EBV nuclear antigens and latent membrane
proteins, have profound effects on cell growth regulation and
are required for EBV latent infection and B cell trans-
formation [1]. Latent membrane protein 1 (LMP1) is
considered the major oncoprotein of EBV, as it transforms
rodent ﬁbroblasts to tumorigenicity in nude mice and is
expressed in HD, NPC, and immunosuppression-associated
tumors [4–8]. In B lymphocytes, LMP1 mimics CD40 signaling,
and both LMP1 and CD40 are essential for EBV-mediated B
cell transformation [9–11]. While CD40 interacts with CD40
ligand expressed on activated T cells to induce B cell
activation and differentiation, LMP1 acts as a constitutive
signal through ligand-independent oligomerization. LMP1
and CD40 interact with the same tumor necrosis factor
receptor–associated factors (TRAFs) leading to activation of
NFjB, c-Jun N terminal kinase (JNK), and p38 MAPK
signaling pathways [12–16]. Activation of NFjB is required
for EBV-induced B cell transformation and its inhibition
rapidly results in cell death [17,18]. Recent studies indicate
that LMP1 also activates phosphatidylinositol 3 kinase (PI3K)/
Akt signaling and that this activation is required for LMP1-
mediated transformation of rodent ﬁbroblasts [5,19].
In vitro, primary B cells can be maintained by CD40
ligation in combination with IL4 treatment. In vivo, CD40
signaling is necessary for germinal center (GC) formation
such that mice deﬁcient for CD40 or CD40L are unable to
form GCs in response to T cell–dependent antigens [20,21].
Both the membrane proximal and distal cytoplasmic regions
of CD40 that bind TRAF6 and TRAFs2/3/5, respectively, are
necessary for GC formation, but either region is sufﬁcient to
induce extrafollicular B cell differentiation and restore low
afﬁnity antibody production [22]. Functionally, LMP1 can
rescue CD40-deﬁcient mice and restore immunoglobulin (Ig)
class switching, most likely because LMP1 recruits similar
TRAF molecules, TRAFs 1/2/3/5 and TRAF6, through the C-
terminal activation regions 1 and 2 domains, respectively.
However, LMP1 is unable to restore afﬁnity maturation and
GC formation [23].
Several EBV transforming proteins have been studied in
transgenic mouse models, however, only LMP1 induces tumor
development when expressed under the control of the Ig
heavy chain promoter and enhancer [24–26]. The LMP1
transgenic mice (IgLMP1) express LMP1 in B lymphocytes,
and in mice older than 12 mo, lymphoma develops with
Editor: Skip Virgin, Washington University School of Medicine, United States of
America
Received April 24, 2007; Accepted September 24, 2007; Published November 9,
2007
Copyright:  2007 Shair et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: BrdU, 5-bromo-29-deoxy-uridine; EBV, Epstein-Barr virus; EMA,
ethidium monoazide; GC, germinal center; GSK3, glycogen synthase kinase 3; HD,
Hodgkin disease; Ig, immunoglobulin; JNK, c-Jun N-terminal kinase; LMP1, latent
membrane protein 1; NPC, nasopharyngeal carcinoma; PI3K, phosphatidylinositol 3
kinase; RPA, Rnase protection assay; TRAF, tumor necrosis factor receptor–
associated factor
* To whom correspondence should be addressed. E-mail: nrt@med.unc.edu
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e166 1669increased incidence (40%–50%) compared to wild-type
control mice (11%), suggesting that LMP1 contributes to
tumor development [26]. The LMP1 lymphomas have
rearranged Ig genes and have activated Akt, JNK, p38, and
NFjB, with speciﬁc activation of the NFjB family member
cRel [27].
In this study, the LMP1 transgenic lymphocytes and
lymphomas were further characterized and their growth
properties in vitro were determined. To obtain pure
populations of malignant lymphocytes and to enable more
detailed biochemical analyses, examples of primary lympho-
mas were inoculated and passaged in SCID mice. Interestingly,
lymphoma development was restricted to B-1a lymphocytes, a
self-replenishing population of cells that are prone to
malignancy [28,29]. LMP1 transgenic lymphocytes had in-
creased viability in vitro and viability was increased by the
addition of IL4. In contrast, both LMP1-positive and -negative
lymphoma cells were independent of IL4 co-stimulation for
survival and proliferation in vitro with a complete absence of
activated Stat6, the IL4 target. The lymphomas were also
distinguished by constitutive activation of Stat3 and dereg-
ulation of the Rb cell cycle pathway. Inhibition of the PI3K/
Akt, NFjB, and Stat3 signaling pathways blocked the
enhanced growth of both LMP1 transgenic and malignant
lymphocytes, suggesting that these pathways are required for
their growth and survival. These appear to be the same targets
that are deregulated in wild-type B-1a lymphomas that arise
spontaneously through age predisposition. This study reveals
that LMP1 promotes malignancy in cells with the inherent
ability to proliferate and that the Akt, NFjB, and Stat3
signaling pathways are required for its growth stimulatory
effects.
Results
High Levels of LMP1 Expression Correlates with the
Development of Lymphoma
LMP1 expression in IgLMP1 mice was directed to B cells
under the control of the Ig heavy chain promoter and
enhancer. It has previously been shown that in these
transgenic mice, LMP1 expression was restricted to B220þ B
cells with lymphoma detected in greatly enlarged spleens
[23,26]. To investigate whether LMP1 expression contributes
to lymphoma development, B cells were puriﬁed from
splenocytes by positive selection using anti-CD19 MACS
magnetic beads, and equivalent amounts of B cells were
analyzed by immunoblotting. LMP1 was detectable in LMP1
transgenic B cells, but upon development of lymphoma,
LMP1 expression was stronger in 5/7 lymphomas analyzed
with concomitant appearance of degradation products
(Figure 1A). To determine whether the higher level of LMP1
detected was due to an expansion of malignant lymphocytes,
expression of LMP1 in the spleen was further evaluated by
immunohistochemical staining. Immunohistochemistry anal-
ysis of spleen sections detected LMP1 in the plasma
membrane of cells in both the follicular white pulp and
circulating lymphocytes in the red pulp (Figure 1B). LMP1
expression was heterogeneous with strong LMP1 staining
interspersed amongst a background of cells staining weakly
for LMP1. Upon development to lymphoma, LMP1 expres-
sion was more abundantly detected with multiple foci of
intense LMP1 staining. This demonstrates that the increased
LMP1 detected by immunoblotting upon malignant progres-
sion reﬂects an increase in LMP1 expression and an
accumulation of cells expressing high levels of LMP1. This
correlation between high LMP1 expression and the develop-
ment of lymphoma suggests that progression to lymphoma
results from increased levels of LMP1.
LMP1 Promotes B-1a Lymphomas That Can Escape Allelic
Exclusion
To determine if LMP1 signaling affects B cell differ-
entiation and to immunophenotype the lymphomas that arise
from LMP1 expression, surface Ig expression of heavy chains
(IgM, IgG, IgD) and light chains (j, k) were analyzed by ﬂow
cytometry. Similar numbers of naı ¨ve (IgMþIgDþIgG ) splenic
B cells with a strong bias towards j light chain were detected
from wild-type or LMP1 transgenic mice, indicating that
LMP1 signaling does not affect B cell maturation (unpub-
lished data). Flow cytometry analysis of the SCID-passaged
wild-type and LMP1 transgenic lymphomas revealed an
IgM
highIgD
low phenotype (Figure 2A), indicative of marginal
zone, B-1, or memory B cells. B-1 cells are further separated
into CD5þ (B-1a) and CD5  (B-1b) subsets. To differentiate
between these cell types, lymphoma cells were further
analyzed for the B-1a marker CD5. All (5/5) of the tested
LMP1 transgenic lymphomas displayed an IgM
highIgD
lowCD5þ
phenotype (Figure 2A), an expression pattern that distin-
guishes B-1a cells. Interestingly, a spontaneous wild-type
lymphoma also developed in B-1a cells (Figure 2A). These
cells are an interesting population that is self replenishing
with an increased likelihood to become malignant in aged
mice [30]. Analysis of LMP1 transgenic mice before the
development of lymphoma showed similar numbers of
splenic B-1a (CD19þCD5þ) and B-1b or B-2 populations
(CD19þCD5 ), indicating that LMP1 does not affect B cell
differentiation (Figure 2B).
Due to allelic exclusion, mature B cells that have been
exposed to antigen will typically express only one heavy chain
isotype (IgG, IgE, or IgA) and either a j or k light chain.
Interestingly, 2/5 LMP1 transgenic lymphomas analyzed
(lymphomas 2 and 4) were doubly positive for low levels of
both j and k light chains (Figure 2A). Previous character-
ization of the LMP1 lymphomas had revealed that the
lymphomas were clonal as determined by Ig heavy chain
rearrangement [26], and analysis of j chain rearrangement
(Figure S1) of the samples analyzed in this study conﬁrmed
clonality. To further assess light chain expression, the
passaged samples were tested by immunoblotting for j and
k light chains (Figure 2C). Interestingly, very low levels of
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Author Summary
Epstein-Barr virus (EBV) is linked to the development of multiple
cancers, including post-transplant lymphoma, Hodgkin disease, and
nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is
expressed in many EBV-associated cancers and is responsible for
most of the altered cellular growth properties that are induced by
EBV infection. This study reveals that LMP1 induces lymphomas in B-
1a lymphocytes, a cell type that is susceptible to transformation in
aged mice. The lymphomas require Akt, NFjB, and Stat3 signaling
for enhanced growth and survival. The activation of the Stat3, Akt,
and NFjB signaling pathways likely underlies the ability of LMP1 to
promote malignant transformation.expression of both light chains were detected by ﬂow
cytometry. The low levels of expression may reﬂect a
limitation of the total number of light chains that can be
expressed on the surface of a B cell. In agreement with the
ﬂow cytometry analysis, LMP1 transgenic lymphomas 2 and 4
were also positive for j and k light chains by immunoblot
analysis (Figure 2C), conﬁrming that these lymphomas
express both light chains. A previous study of mice that
developed leukemia due to an expansion of self-reactive B-1a
cells determined that the B-1a leukemias were also doubly
positive for j and k light chains [31]. These ﬁndings indicate
that expression of LMP1 in B-1a cells promotes the develop-
ment of malignancy and can result in the aberrant escape
from allelic exclusion.
LMP1 Promotes B Cell Survival and Proliferation In Vitro
Primary B cell cultures can be maintained through CD40
ligation and supplementation with IL4 [32]. To investigate
whether LMP1 affects primary B cell survival and prolifer-
ation, splenocytes were cultured in the presence or absence
of IL4 and analyzed by MTS as a metabolic marker, by
ethidium monoazide (EMA) exclusion for viability, and by 5-
bromo-29-deoxy-uridine (BrdU) incorporation for prolifer-
ation. In the MTS assay, as expected, splenocytes from wild-
type mice did not survive even with the addition of IL4 due to
a lack of CD40 ligation (Figure 3A). In contrast, LMP1
splenocytes had increased metabolism even in the absence of
IL4, which was further enhanced upon addition of IL4. Wild-
type and LMP1 transgenic lymphoma cells had high levels of
MTS activity even in the absence of IL4 (Figure 3A). The
LMP1 transgenic lymphoma cells had approximately 4-fold
higher MTS activity than the normal transgenic lymphocytes
and were at least 2-fold higher than the control lymphoma. As
previously published, lymphoma usually develops in mice
over 12 mo of age and all mice are sacriﬁced by 18–20 mo.
The ages of the transgenic mice with or without lymphoma
ranged between 6 and 20 mo old. There was no correlation
between age and MTS activity.
EMA exclusion of CD19þ gated B cells prepared from two
Figure 1. High LMP1 Expression Correlates with the Development of Lymphoma
LMP1 expression is shown by (A) immunoblotting of purified B cells (CD19þ) and (B) immunohistochemistry staining of spleen tissue from wild-type
(WT) and LMP1 transgenic mice.
(A) Lymphomas are identified with a number (1–7). Arrows indicate the LMP1-specific band and its degradation products as well as a non-specific band.
Actin was used as a loading control.
(B) White and red pulps are shown, but this architecture is lost upon development of lymphoma. Scale bar, 20 lm.
doi:10.1371/journal.ppat.0030166.g001
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increase in viability in the LMP1 transgenic lymphocytes
compared to wild-type lymphocytes. Two examples of LMP1
transgenic lymphoma cells had greatly increased viability that
was not increased by IL4 treatment, indicating that the
lymphoma cells are independent of IL4 co-stimulation
(Figure 3B). Enhancement in MTS activity was observed in
LMP1 transgenic lymphoma cells by the addition of IL4;
however, EMA exclusion did not reveal a similar increase.
This could reﬂect a difference for IL4 requirement in the
metabolic activity versus the viability of LMP1 transgenic
lymphoma cells. Although expression of LMP1 could enhance
survival of non-malignant primary lymphocytes, BrdU incor-
poration revealed that LMP1 expression alone was not
sufﬁcient to induce proliferation in culture (unpublished
data). Only lymphoma cells had detectable levels of BrdU
incorporation detected by ﬂow cytometry (Figure 3C).
Interestingly, LMP1 lymphoma cells had signiﬁcantly higher
levels of proliferation in comparison to the spontaneous
lymphoma that developed in an LMP1-negative littermate
(25% versus 4%). This higher level of proliferation was
observed in lymphomas that express both high (Table 1,
LMP1-L2 and LMP1-L3) and low (Table 1, LMP1-L5) levels of
LMP1, suggesting that even small amounts of LMP1 is
sufﬁcient to induce dramatic effects in proliferation. The
level of proliferation was not enhanced upon IL4 addition,
conﬁrming the IL4 independence observed in the viability
studies (Figure 3C; Table1).
Wild-Type and LMP1 Transgenic Lymphoma Cells Do Not
Require IL4 and Stat6 Signaling
To investigate whether IL4 independence was due to
endogenous IL4 expression, IL4 transcription was assessed
by an Rnase protection assay (RPA). IL4 transcription was
detectable with control RNA and faintly in the mouse
lymphoma cell line K46l (Figure 4A). However, IL4 tran-
scription was not detectable in CD19þMACS-puriﬁed B cells
from wild-type lymphocytes (unpublished data), LMP1 trans-
genic lymphocytes, or lymphoma cells, although the GAPDH
and L32 controls were effectively protected (Figure 4A).
Activated Stat6 (pStat6), a target of the IL4 receptor pathway,
was detected in the wild-type and LMP1 transgenic lympho-
cytes (Figure 4B). In contrast, pStat6 was barely detected in
either the wild-type or LMP1 transgenic lymphoma cells.
However, the pathway was not disabled, as treatment of the
lymphoma cells with IL4 induced Stat6 phosphorylation
(Figure 4C).
Although wild-type lymphocytes cannot be maintained in
culture with IL4 supplementation alone (Figure 3A), slight
enhancement in MTS activity could be detected if the cells
were analyzed at an earlier time point, at 1 d (Figure 4D)
Figure 2. LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion
(A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan–B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM
and IgD) and light chain (j and k) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated
on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for
j and k light chains.
(B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19þCD5þ) and B-1b or B2 subsets (CD19þCD5 ). Percentages of B-1a and
B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results.
(C) Immunoblot analysis for j and k light chains of B cells (CD19þ) purified from WT and LMP1 transgenic mice. Actin was used as a loading control.
doi:10.1371/journal.ppat.0030166.g002
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activity induced by IL4 in wild-type lymphocytes could be
neutralized by the addition of IL4 antibody (Figure 4D).
However, neutralizing antibodies to IL4 did not affect the
MTS activity of LMP1 transgenic lymphoma cells (Figure 4E).
In summary, the wild-type and LMP1 transgenic lymphoma
cells grew independently of IL4 treatment and did not
require Stat6 signaling.
LMP1 Upregulates IL10 and Constitutively Activates Stat3
To identify cytokines that may contribute to the increased
survival and growth of lymphomas, the expression levels of a
panel of cytokines were screened on CD19þMACS-puriﬁed B
cells, using an RPA probe set for IL4, IL5, IL10, IL13, IL15,
IL9, IL2, IL6, and IFNc. Expression levels were quantiﬁed with
a phosphorimager and normalized to the ribosomal house-
keeping gene L32. None of the tested cytokines were detected
in wild-type lymphocytes, therefore cytokine:L32 ratios were
set to 1 in the mouse B cell lymphoma line 967. Transcription
of IL10, IL15, and IFNc were reproducibly detected in LMP1
transgenic lymphocytes and lymphoma cells and was higher
than in the B cell lymphoma cell lines 967 and K46l (Figure
5A). There was no signiﬁcant difference in the expression of
IL15 and IFNc between LMP1 transgenic lymphocytes and
Figure 3. LMP1 Promotes B Cell Survival and Proliferation In Vitro
(A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4
for 3 d. The results are the mean 6 SEM of triplicate samples averaged from multiple mice where ‘‘n’’ the number of mice analyzed is as follows: n¼2
for WT lymphocytes and WT lymphomas, n ¼ 11 for LMP1 transgenic lymphocytes, and n ¼ 13 for LMP1 transgenic lymphomas.
(B) EMA exclusion of CD19þgated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or
without (black bars) IL4 for 2 d.
(C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results
from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.
doi:10.1371/journal.ppat.0030166.g003
Table 1. Summary of Analysis Performed on Wild-Type and LMP1 Transgenic Lymphomas
Lymphoma LMP1
Levels
Immunophenotype Clonality
(j locus)
Viability Proliferation Pathways Activated
 IL4 þIL4  IL4 þIL4 Stat6 Stat3 Akt Rb
WT-L 1   IgM
highIgD
lowCD5
þj
þk
  VJ1 53% 69% 4% 4%  þþ þ
LMP1 -L 1 þþþ IgM
highIgD
lowCD5
þj
þk
  VJ2  þþ þ
2 þþþ IgM
highIgD
lowCD5
þj
þk
þ VJ5 97% 96% 25% 26% þþ þ
3 þþ IgM
highIgD
lowCD5
þj
þk
  VJ5 92% 93% 24% 33%  þþ þ
4 þþ IgM
highIgD
lowCD5
þj
þk
þ VJ2
5 þ VJ4 29% 34%
6 þþ IgM
highIgD
lowCD5
þj
þk
  VJ2
7 þ
Levels of LMP1 expression are indicated by (þ) moderate, (þþ) strong, (þþþ) very strong, or ( ) not detected. For viability and proliferation assays, splenocytes were cultured with or
without IL4 supplementation and percentages depict CD19þB cells as determined by flow cytometry. The pathways activated are indicated by the enhanced presence (þ) or absence ( )
of the activated signals. WT-L: wild-type lymphoma; LMP1-L: LMP1 transgenic lymphoma.
doi:10.1371/journal.ppat.0030166.t001
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IFNc is induced by LMP1 expression in healthy lymphocytes
but is not a unique property of malignant lymphocytes.
Strikingly, IL10, a B lymphocyte stimulatory cytokine, was
increased 1.5- to 5-fold in the wild-type and LMP1 transgenic
lymphoma cells compared to LMP1 transgenic lymphocytes
(Figure 5A). Production of IL15 and IFNc has been associated
with induction of cytotoxic effector responses in cells latently
infected with EBV [33,34]. However, transformation and
growth properties induced by EBV are associated with the
upregulation of IL10 [35–38]; hence, the effects of IL10
upregulation on the growth properties of the lymphoma cells
were further examined. Immunoblot analysis indicated that
LMP1 transgenic lymphocytes and wild-type and LMP1
transgenic lymphoma cells had corresponding increased
levels of phosphorylated a and b isoforms of activated Stat3,
a target of the IL10 receptor (Figure 5B). However, when
comparing the same lymphomas, there was no correlation
between the levels of IL10 induction and the levels of Stat3
activation. This suggests that the activation of Stat3 is not
solely induced by IL10 or that Stat3 activation may be
constitutive. Additionally, there was no correlation between
the levels of LMP1 expression and the levels of IL10 induction
(Figures 1A and 5A). This indicates that the induction of IL10
is a general property associated with enhanced survival and
may only be indirectly affected by LMP1. Neutralizing
antibodies to IL10 did not affect the survival of lymphoma
cells as determined by the MTS assay (unpublished data),
suggesting constitutive activation of Stat3. This was con-
ﬁrmed by immunoblot analysis such that in the presence of
anti-IL10 neutralizing antibodies, pStat3 levels remained
activated in lymphoma cells isolated from wild-type and
LMP1 transgenic lymphomas (Figure 5C). Exogenous addition
of IL10 enhanced pStat3 activation above constitutive levels,
indicating that lymphoma cells are responsive to IL10
treatment (Figure 5C). This means that although the
lymphoma cells have constitutive Stat3 activation, it may be
further enhanced by IL10 induction. The neutralizing effect
of the anti-IL10 antibody was conﬁrmed by pre-incubation of
IL10 with anti-IL10 antibody compared to a rat IgG1 isotype
control (Figure 5C).
Nuclear translocation of pStat3 is a consequence of
activation, and nuclear pStat3 was not detected by immuno-
histochemistry staining of spleen sections from control mice.
However, nuclear pStat3 was detectable in LMP1 transgenic
mice and wild-type lymphomas and was detected more
homogeneously in LMP1 transgenic lymphomas (Figure 5D).
The constitutive activation of pStat3 and abundant nuclear
Stat3 suggests that Stat3 signaling contributes to LMP1-
mediated lymphoma development.
Figure 4. Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture
(A) Rnase protection assay for IL4 mRNA from purified B cells (CD19þ) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping
genes were used as a loading control. Arrow indicates the position of the protected probe.
(B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19þ) at the time of harvest or in (C) whole
splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced
out.
(D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype
control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean 6 SEM of triplicate samples
from a single representative experiment that was repeated twice with similar results.
doi:10.1371/journal.ppat.0030166.g004
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Cycle Pathway
LMP1 transformation of rodent ﬁbroblasts requires acti-
vation of PI3K and Akt [5]. Additionally, activated pAkt is
frequently detected in NPC and the neoplastic Reed-Stern-
berg cells of classical HD [39,40]. To determine if Akt
signaling is activated in LMP1 transgenic mice, pAkt and
several of its targets were assessed by immunoblotting of
splenic CD19þ MACS-puriﬁed B cells. LMP1 transgenic B
cells had increased levels of pAkt compared to wild-type
lymphocytes; however, progression to lymphoma in both
LMP1-positive and -negative lymphoma cells did not further
increase pAkt levels. The Akt target glycogen synthase kinase
3 (GSK3) is inactivated by phosphorylation; however, in-
creased phosphorylated GSK3 was not detected in the
transgenic lymphocytes and was almost absent in the
lymphoma samples (Figure 6A). This ﬁnding indicates that
GSK3 is not a target of activated Akt in the LMP1 transgenic
lymphocytes and lymphoma cells. Similarly, activation of Akt
without phosphorylation of GSK3 has been previously shown
in EBV-positive HD [40]. In contrast, the wild-type lympho-
cytes lacked activated Akt but did have detectable phosphory-
Figure 5. LMP1 Upregulates IL10 Expression and Constitutively Activates Stat3
(A) Relative expression of IL10, IL15, and IFNc mRNA in WT and LMP1 transgenic B cells (CD19þ), as detected with an Rnase protection assay. Mouse
lymphoma cell lines 967 and K46l were used as controls. Expression levels were quantified with a phosphorimager and values were normalized to the
ribosomal housekeeping gene L32. The cytokine:L32 ratio was set to 1 in the mouse B cell lymphoma line 967.
(B and C) Immunoblot analysis of activated pStat3 in purified B cells (CD19þ) from WT and LMP1 transgenic mice (B) at the time of harvest, and (C) 4 h
after culture with or without IL10, a neutralizing antibody to IL10, or a rat IgG1 isotype control. (C) Shown are the results for WT lymphoma 1 and LMP1
transgenic lymphoma 1. Arrows indicate the positions of the a and b isoforms of Stat3. Actin was used as a loading control.
(D) Immunohistochemistry detection of activated nuclear pStat3 in the spleens of WT and LMP1 transgenic mice. Scale bar, 20 lm.
doi:10.1371/journal.ppat.0030166.g005
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are involved in the regulation of GSK3.
To identify other potential Akt targets, immunoblot
analysis for p-mTOR was performed. Activated p-mTOR
was not increased in LMP1 transgenic lymphocytes or
lymphoma cells, indicating that this pathway is not affected
by LMP1-induced Akt activation and does not contribute to
lymphoma development (Figure 6B). Akt is also known to
phosphorylate and induce the degradation of the pro-
apoptotic Forkhead family of transcription factors, leading
to cell cycle progression and survival in some human tumors
[41,42]. Immunoblot analysis of splenic B cells did not
consistently detect p-FoxO1 levels, a signal that targets
FoxO1 for degradation. Hence, degradation of FoxO1 was
assessed by detection of total FoxO1 levels. Immunoblot
analysis indicated that total FoxO1 levels were greatly
decreased in wild-type and LMP1 transgenic lymphomas
(Figure 6B), suggesting that inhibition of the Forkhead
signaling pathway is an important target of Akt in lymphoma
development. However, considering that Akt activation did
not induce FoxO1 degradation in LMP1 transgenic B cells,
Akt may not be the sole regulator of FoxO1, and it may be
that progression to lymphoma requires modulation of multi-
ple pathways.
The Forkhead family of transcription factors is known to
induce the expression of the Cdk inhibitor p27 [43,44]. LMP1-
transformed rodent ﬁbroblasts have decreased expression of
p27, upregulation of Cdk2, and subsequent phosphorylation
and inactivation of the tumor suppressor gene Rb [45]. To
investigate whether LMP1 affected cell cycle regulation
through the Rb pathway in B cells, immunoblot analyses for
pRb, Cdk2, and p27 were performed on splenic CD19þ
MACS-puriﬁed B cells. LMP1 transgenic B cells had enhanced
levels of pRb with concomitant stabilization of total Rb levels
and Cdk2 compared to wild-type B lymphocytes (Figure 6C).
Progression to lymphoma in both wild-type and LMP1
transgenic lymphoma cells led to increased levels of Rb,
correspondingly high levels of Cdk2, and decreased levels of
p27 (Figure 6C). These data indicate that the Rb pathway is
deregulated in LMP1 transgenic lymphocytes and that
lymphoma cells are distinguished by loss of FoxO1 and
decreased p27.
LMP1 Promotes Tumor Growth and Survival through
Activation of Akt, NFjB, and Stat3 Pathways
To explore which pathways were required for the enhanced
growth and survival of LMP1-induced lymphomas, spleno-
cytes from wild-type and LMP1 transgenic mice were cultured
in the presence of inhibitors for Akt, NFjB, Stat3, mTOR, or
MAPK and assayed for growth and survival by the MTS assay.
As previously shown, wild-type lymphocytes were not viable
in culture and could not be tested with the inhibitors.
However, the enhanced viability of LMP1 transgenic lym-
Figure 6. LMP1 Activates Akt Signaling and Deregulates the Rb Cell Cycle Pathway
(A and B) Immunoblot analysis of purified B cells (CD19þ) from the spleens of WT and LMP1 transgenic mice for Akt signaling, probing for (A) activated
pAkt and downstream targets, including inactivated pGSK3a/b, and (B) activated p-mTOR, and total levels of FoxO1. Arrows indicate the positions of a
and b isoforms of GSK3. The white line indicates that intervening lanes have been spliced out.
(C) Immunoblot analysis for cell cycle proteins regulating the Rb pathway, probing for activated pRb, and total levels of Cdk2 and the Cdk inhibitor p27.
Actin was used as a loading control.
doi:10.1371/journal.ppat.0030166.g006
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ibine, BAY11–7085, cucurbitacin I, and slightly with
SB203580, but not by treatment with rapamycin, U0126, or
AG490 (Figure 7). Triciribine inhibits the activation of Akt
and at 20 lM has been shown to induce growth arrest in
cancer cells with aberrant Akt activity [46]. The effects of
triciribine on cell growth of the transgenic lymphocytes and
lymphomas were apparent as low as 1 lM, suggesting that
activation of Akt is required for the survival and growth of
LMP1 transgenic lymphocytes and lymphoma cells (Figure 7).
The effects of the inhibitors were assessed by identifying
phosphorylated Akt, Stat3, and total levels of IjBa (Figure 8).
Treatment with triciribine effectively blocked phosphoryla-
tion of Akt, and phosphorylated Akt was no longer detected
past 5 lM. Phosphorylated Stat3 and IjBa were still present at
25 lM. These ﬁndings suggest that triciribine speciﬁcally
Figure 7. Akt, NFjB, and Stat3 Signaling Are Required for the Growth and Survival of Lymphoma Cells
MTS assay of splenocytes from (A and B) WT or (C and D) LMP1 transgenic lymphomas and (E and F) LMP1 transgenic lymphoctyes. Splenocytes were
cultured with or without inhibitors of NFjB (BAY11), mTOR (rapamycin), Akt (triciribine), MEK1/2 (U0126), p38 (SB202190), or Stat3 (cucurbitacin I and
AG490) at the indicated concentrations. The results are the mean 6 SEM of triplicate samples. Shown are the results for (A and B) WT lymphoma 1, (C
and D) LMP1 transgenic lymphoma 2, and (E and F) one out of two LMP1 transgenic mice analyzed. This analysis was repeated with LMP1 transgenic
lymphoma 4 yielding similar results.
doi:10.1371/journal.ppat.0030166.g007
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enhanced viability of the transgenic lymphocytes and
lymphoma cells.
Inhibition of NFjB signaling rapidly induces cell death of
EBV-transformed lymphocytes [17,18]. BAY11–7085, an in-
hibitor of NFjB signaling, also greatly decreased the viability
of the LMP1 transgenic lymphocytes and lymphoma cells at
doses as low as 1 lM, and at 5 lM the cells were completely
nonviable (Figure 7). This is well within the reported IC50 of
10 lM. Phosphorylated Akt, Stat3, and total IjBa were still
present up to treatment with 15 lM and then were no longer
detected (Figure 8). This ﬁnding suggests that inhibition of
NFjB can induce cell death in LMP1 transgenic lymphocytes
and lymphoma cells without signiﬁcant effects on activation
of Akt or Stat3.
Cucurbitacin I inhibits activation of Stat3 by suppressing
the activation of its kinase JAK2. It has been shown to
selectively inhibit the growth of tumors with constitutively
activated Stat3 [47]. Similarly, LMP1 transgenic lymphocytes
and lymphoma cells were susceptible to cucurbitacin I
treatment starting at 0.1 lM, a dose that corresponds closely
to the reported IC50 of 500 nM (Figure 7) [47]. Phosphory-
lated Akt, Stat3, and total IjBa were not detectable past 1 lM
and at higher doses all protein levels were greatly decreased,
Figure 8. Analysis of Akt, NFjB, and Stat3 Pathways in Contribution to the Growth and Survival of Lymphoma Cells
(A–D) Immunoblot analysis of wild-type and LMP1 transgenic lymphomas for Akt, NFjB, and Stat3 signaling after treatment with (A) an Akt inhibitor,
triciribine, (B) an NFjB inhibitor, BAY11–7085, and the Stat3 inhibitors (C) cucurbitacin I and (D) AG490, at the indicated concentrations. Arrows indicate
the positions of a and b isoforms of Stat3. Actin was used as a loading control.
doi:10.1371/journal.ppat.0030166.g008
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reported inhibitor of Stat3, AG490, had no effect on growth
(Figure 7), but activation of Akt, Stat3, or levels of IjBa were
also not affected (Figure 8). These ﬁndings suggest that
inhibition of Stat3 can induce cell death in LMP1 transgenic
lymphocytes and lymphoma cells, but Stat3 inhibition also
has considerable crossover effects on Akt and NFjB signaling.
LMP1 has also been shown to activate JNK and p38 MAPK
pathways [13,48], and LMP1 transgenic lymphocytes were
mildly susceptible to growth inhibition by SB202190, an
inhibitor of p38 MAPK, but not U0126, an inhibitor of MEK1/
2 activity. However, effects of SB202190 were only apparent
at high doses (.10 lM), much higher than the reported IC50
of 0.35 lM, suggesting that p38 MAPK does not signiﬁcantly
contribute to the enhanced viability in LMP1 transgenic
lymphocytes or lymphoma cells (Figure 7). Interestingly, both
wild-type and LMP1 transgenic lymphomas were similarly
susceptible to triciribine, BAY11–7085, and cucurbitacin I
treatments, but not SB202190, AG490, or U0126 treatment,
suggesting that activation of Akt, NFjB, and Stat3 but not
MAPK pathways are characteristics associated with malignant
transformation (Figure 7). rapamycin, an inhibitor of mTOR,
did not affect the viability of the transgenic lymphocytes or
lymphoma cells, conﬁrming that mTOR is not targeted by Akt
activation in LMP1 transgenic lymphocytes or malignant
lymphoma cells (Figure 7).
Discussion
This study deﬁnes the oncogenic properties of LMP1 in
promoting B cell lymphomagenesis. LMP1 transgenic mice
have a higher incidence of lymphoma [26] and the pro-
gression to lymphoma correlates with higher expression
levels of LMP1 (Figure 1A and 1B), suggesting that LMP1 is
directly involved in tumor development. Table 1 summarizes
the biological and molecular properties that were identiﬁed
in wild-type and LMP1 transgenic lymphomas. Although
many of the molecular properties studied were similar
between wild-type and LMP1 transgenic lymphomas, there
were distinguishing biological properties, namely the ability
of LMP1 transgenic lymphomas to induce higher levels of
survival and proliferation. Interestingly, although LMP1
transgenic mice develop lymphomas in the same B-1a cell
type as spontaneous wild-type lymphomas (Figure 2), some
signaling effects induced by LMP1 may explain the enhanced
promotion to lymphomagenesis. Since CD40-deﬁcient mice
have decreased numbers of IgM
highIgD
low cells, a phenotype
associated with B-1, marginal zone, and memory B cells, the
mimicry of CD40 signaling by LMP1 could possibly contrib-
ute to the expansion of B-1 cells [20]. It is noteworthy that
expression of LMP1 in transgenic mice has been shown to
inhibit the formation of GCs [23,49], preventing typical B-2
cells from antigen-driven selection and expansion. The lack
of GC reactions may contribute to the bias of LMP1
transgenic mice towards B-1 cell lymphomas. Interestingly,
LMP2 signaling also favors development of B-1 cells, but this
occurs in the absence of transformation. These results suggest
that the mimicry of B cell receptor signaling by LMP2
promotes B-1 cell differentiation but not transformation
[24,50,51]. This promotion of B-1 differentiation may account
for the ability of LMP2 to exacerbate autoimmunity and
bypass anergy induction [52,53]. In contrast, the preponder-
ance of tumors of B-1a origin does not reﬂect effects of LMP1
signaling on B cell differentiation, as splenic B cells from
healthy LMP1 transgenic mice contain similar numbers of B-1
and B-2 cells as wild-type mice. In support of this lack of
effect, the differentiation of B-1 versus B-2 cells is thought to
be independent of CD40 signaling [54].
B-1 cells constitute the predominant lymphocyte popula-
tion in the peritoneal and pleuropericardial cavities, while B-
2 cells are mainly found in the spleen, lymph node, and
peripheral blood. B-1 cells produce the main source of IgM
and IgA antibodies in serum, which are involved in T cell–
independent responses to common microbial antigens.
Importantly, B-1 cells have the unique capacity to self
replenish and are also predisposed to transformation
[28,29]. Clonal expansion of B-1 cells can be detected in
aging mice above 18 mo of age, and B-1 cells are thought to be
the murine progenitor of B cell chronic lymphocytic
leukemia [30]. The data presented in this study indicate that
although LMP1 is expressed in all B lymphocytes in the
transgenic mice, malignancy develops in this speciﬁc subset of
B cells. The elevated expression of LMP1 in B-1a cells and the
activation of speciﬁc pathways apparently induce malignant
growth. These same pathways can also become sporadically
activated in aged mice and also result in lymphoma develop-
ment. This is similar to EBV-associated cancers in vivo, where
pathways that are activated by LMP1 are also activated in the
less prevalent EBV-negative forms of the cancers [40,55–58].
Thus, the contribution of EBV and LMP1 to tumor develop-
ment is apparently the continuous activation of pathways that
can also be sporadically activated and contribute to tumor
development.
The lymphomas were marked by the upregulation of IL10,
constitutive activation of Stat3 signaling, and a requirement
for activation of Akt, NFjB, and Stat3 pathways (Figures 5
and 7). Induction of IL10 is associated with the trans-
formation of B-1 lymphomas in mice [59,60] and is frequently
associated with EBV-positive B cell malignancies acting as a B
cell growth factor [35–38]. In addition, LMP1 has been shown
to stimulate IL10 expression in Burkitt lymphoma cell lines
[61,62]. This suggests that although Stat3 is constitutively
activated in the lymphoma cells, the induction of IL10 may
further enhance Stat3 activation or may contribute to other
IL10-responsive signaling pathways.
LMP1 activates both the canonical and non-canonical
pathways of NFjB signaling [14,63–65], and inhibition of
NFjB blocked the survival of LMP1 transgenic lymphocytes
and LMP1-positive and -negative lymphoma cells. NFjB and
PI3K signaling are crucial for CD40-induced proliferation,
and mice deﬁcient for cRel or the p85 regulatory subunit of
PI3K are unresponsive to mitogenic stimuli, including CD40
ligation [66–68]. We have previously shown that cRel is
speciﬁcally activated in both wild-type and LMP1 transgenic
lymphomas, suggesting that activation of cRel is associated
with B cell transformation [27]. Our observations suggest that
similar to CD40-induced proliferation, LMP1 induces pro-
liferation through PI3K-mediated activation of Akt and
activation of NFjB components such as cRel. CD40 also
induces downregulation of the cell cycle inhibitor p27
through a PI3K-dependent manner, and the LMP1 lymphoma
cells also had decreased levels of p27 with phosphorylation of
Rb and increased Cdk2 (Figure 6C) [66]. Although LMP1 has
been shown to deregulate the Rb pathway in epithelial cells
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property in B lymphocytes.
The requirement for Akt activation was conﬁrmed by the
striking inhibition of lymphoma viability by triciribine, an
Akt inhibitor. However, the activated pAkt did not lead to
phosphorylation and inactivation of the downstream target
GSK3 (Figure 6A). This effect has also been described in EBV-
positive HD biopsies [40]. In contrast, rapamycin, U0126, and
SB202190 did not affect the survival of LMP1 transgenic
lymphocytes or the wild-type and LMP1 transgenic lympho-
ma cells (Figure 7A, 7C, and 7E). This lack of effect by
rapamycin conﬁrmed the absence of activated p-mTOR levels
(Figure 6B). These ﬁndings suggest that other Akt targets
contribute to malignant progression. One key target is likely
the inhibition of the Fox01 transcription factors. Repression
of the pro-apoptotic transcription factor FoxO1 in a PI3K-
dependent manner can inhibit expression of bcl6, a tran-
scription factor necessary for GC formation [49,70]. It has
been shown that overstimulation of CD40 signaling with
agonistic antibodies inhibits GC formation [71]. Similarly,
due to mimicry of CD40 signaling, transgenic LMP1 mice are
also defective in GC formation [23,49]. The constitutive
signaling by LMP1 likely blocks GC formation through
downregulation of bcl6. Interestingly, clinical studies indicate
that expression of LMP1 and bcl6 are mutually exclusive in
non-HD and classical HD [72,73]. Thus, the LMP1 transgenic
lymphomas mirror aspects of EBV-induced HD. Although the
activation of Akt and the lack of Fox01 in the lymphoma cells
suggest that LMP1 affects bcl6 and GC formation through this
pathway, regulation of other Forkhead targets involved in cell
cycle progression, such as p27 and CyclinD2, likely contribute
to malignant transformation. Indeed, loss of FoxO1 expres-
sion in lymphoma cells correlated with a loss of p27 (Figure
6B and 6C). CyclinD2 has also been shown to be upregulated
by LMP1 through release of FoxO1-mediated repression [70].
In summary, in this transgenic model of lymphomagenesis,
LMP1 promotes malignancy in B-1a cells, a population that is
predisposed to clonal expansion with age. The malignant
lymphocytes were distinguished by constitutively active Stat3
signaling, decreased p27, and activated Akt and NFjB
pathways, properties that are associated with promoting the
growth and survival of B lymphocytes. Importantly, Akt,
NFjB, and Stat3 pathways were critically required for the
growth and survival of malignant lymphocytes as well as
healthy LMP1 transgenic lymphocytes. The growth of EBV-
transformed lymphocytes also requires activation of NFjB,
and these studies provide insight into how LMP1 contributes
to EBV-associated transformation. The transgenic lympho-
mas mirror multiple aspects of EBV-induced tumors and
suggest that in vivo these properties of LMP1 are major
factors in the development of cancer.
Materials and Methods
Transgenic mice. Generation of LMP1 mice under the Ig heavy
chain promoter and enhancer have been described previously and
were maintained as heterozygotes on a Balbc background [26]. LMP1
mice were genotyped by Southern blot and PCR analysis of tail DNA
as described previously [26]. Spleen and liver sections were ﬁxed in
4% paraformaldehyde and embedded in parafﬁn, and 5-lm sections
were stained with hematoxylin and eosin for histopathological
analysis. Lymphomas were passaged by intraperitoneal injection of
1310
8 splenocytes into SCID mice and sacriﬁced upon development
of an extended abdomen. Animals were housed in the Association for
Assessment and Accreditation for Animal Care–approved animal
facility at the University of North Carolina at Chapel Hill. All
protocols were approved by the Institutional Animal Care and Use
Committee.
Isolation and growth of B cells. Splenocytes were prepared by
homogenizing spleen tissue with two frosted slides and debris was
ﬁltered through a 100-lm cell strainer. Erythrocytes were lysed using
0.8% ammonium chloride solution (StemCell Technologies) for 10
min on ice and washed twice with PBS. B cells were isolated using
CD19-MACS beads according to the manufacturer’s instructions
(Miltenyi Biotec) and grown in Iscove’s medium supplemented with
heat-inactivated 10% fetal bovine serum and antibiotic/antimycotic
(GIBCO). Splenocytes isolated from SCID-passaged lymphomas
consisted of 80%–90% B cells as determined by ﬂow cytometry,
and were hence not further puriﬁed with CD19-MACS beads.
Splenocytes were seeded at 1.25 3 10
6 cells/ml and where applicable,
recombinant mouse IL4 was added at 100 ng/ml, recombinant mouse
IL10 at 10 ng/ml, and rat IgG1 anti-mouse IL10 and rat IgG1 isotype
control at 10 lg/ml (R&D Systems). For BrdU incorporation assays,
splenocytes were pulsed for 24 h with 10 lM BrdU 1 d post-harvest.
MTS assay. The 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) cell cyto-
toxicity/proliferation assays were performed using the CellTiter 96
aqueous one-solution cell proliferation assay (Promega), according to
manufacturer’s instructions. For IL4 studies, splenocytes were
cultured for 3 d in the presence or absence of 100 ng/ml IL4. Cells
were seeded on day 3 in triplicate in a 96-well plate at 2.5310
6 cells/
ml at 100 ll per well. MTS reagent was added for 4 h and absorbance
was read at 540 nm; values plotted were subtracted from blanks. For
neutralization assays, splenocytes were seeded at 5 3 10
6 cells/ml at
100 ll per well on day of harvest and IL4, rat IgG1 anti-mouse IL4, or
rat IgG1 isotype control (R&D Systems) were added at the concen-
trations indicated in the ﬁgures. Cultures were pulsed for 4 h with
MTS reagent 1 d post-seeding. For inhibitor studies, splenocytes were
seeded at 1 3 10
7 cells/ml at 100 ll per well on day of harvest, and
inhibitors were added at the concentrations indicated in the ﬁgures.
The inhibitors BAY11–7085, rapamycin, triciribine, U0126,
SB202190, and cucurbitacin I were purchased from EMD Biosciences.
For non-malignant splenocyte cultures, B cell activation was induced
with 10 lg/ml of goat F(ab’) anti-mouse IgM (Jackson ImmunoR-
esearch). Cultures were pulsed for 4 h with MTS reagent 1 d post-
seeding.
Immunohistochemistry. Parafﬁn-embedded spleen sections were
deparafﬁnized in Histoclear (National Diagnostics) and rehydrated in
graded ethanol. Sections were antigen retrieved by microwaving in
citrate buffer (pH 6.0) for 15 min (LMP1 staining) and 10 min (pStat3
staining). For LMP1 staining, sections were blocked with 1% BSA and
0.1% cold ﬁsh skin gelatin followed with streptavidin/biotin block
(Vector Labs). Rat IgG anti-LMP1 (clones 8G3 and 1G6, Ascenion)
were used at 1:10 dilution from tissue culture supernatants, followed
with 8 lg/ml biotinylated mouse F(ab’) anti-rat IgG (HþL) pre-
adsorbed to mouse serum (Jackson ImmunoResearch) and 2 lg/ml
streptavidin-alkaline phosphatase conjugate (Jackson ImmunoRe-
search). Stains were developed with BCIP/NBT and counterstained
in Nuclear Fast Red (Dako). Phospho-Stat3 was detected with 4 lg/ml
of pStat3 antibody (Tyr705, Cell Signaling) and detected with anti-
rabbit Poly-HRP IHC detection kit (Chemicon).
Flow cytometry. One million splenocytes were stained with the
appropriate primary antibody unconjugated or conjugated to FITC,
PE, or APC diluted in stain buffer (PBS with 3% FBS). For BrdU
detection, the FITC-BrdU ﬂow kit was used as instructed by the
manufacturer (BD Bioscience). Brieﬂy, cells were exposed to EMA
(Molecular Probes) for exclusion of dead cells, stained for surface
antigens, ﬁxed in paraformaldehyde, and permeabilized with saponin.
To expose BrdU epitopes, cells were treated with Dnase and stained
with FITC-conjugated anti-BrdU antibody. Flow cytometry was
performed on FACScalibur using the CellQuest program (Becton
Dickinson). Further analysis was conducted on the Summit v4.2
program (Dako).
Rnase protection assay. Total RNA was isolated from CD19þ
MACS-puriﬁed B cells using the Rneasy midi puriﬁcation kit with
Dnase treatment, according to the manufacturer’s instructions
(Qiagen). The mCK-1 probe template set (BD Biosciences) was
labeled using the In Vitro Transcription Kit according to the
manufacturer’s instructions (BD Biosciences). Brieﬂy, 50 ng of
mCK-1 probe set was labeled with [a-
32P]UTP using T7 RNA
polymerase and puriﬁed using Sephadex G-50 columns (NucAway
Spin column, Ambion). The labeled probe was quantitated using a
scintillation counter, and 6 3 10
5 cherenkov cpm was used to
hybridize to 4 lg of total RNA using the RPA kit (BD Biosciences).
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Single-stranded RNA was digested with a mixture of Rnase A and T1,
and precipitated using isopropanol. Protected probes were resolved
on a denaturing 4.75% acrylamide gel, dried, and imaged using a
phosphorImager (Molecular Dynamics). Densitometry was performed
using the ImageQuant TL v2005 software (GE Healthcare).
PCR analysis of j chain rearrangement. DNA was isolated from
splenocytes using the Dneasy Tissue Kit (Qiagen), with Rnase
treatment. PCR reactions contained 100 ng of genomic DNA, 0.2
lM each primer, 0.2 mM dNTPs, and 2.5 U Taq DNA polymerase
(NEB) performed in 1X ThermoPol buffer (NEB). Primers used were
Vjcon and Jj5–18 and have been described previously [74]. PCR
conditions were 94 8C for 2 min, 40 cycles of 94 8C for 30 s, 63 8C for
90 s, and 72 8C for 1 min, followed by 1 cycle of 72 8C for 5 min.
Immunoblot analysis. Whole cell lysates were prepared in radio-
immunoprecipitation assay (RIPA) buffer (20 mM Tris-HCl [pH 7.5],
150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.1% sodium
deoxycholate) supplemented with 2 mM phenylmethylsulfonyl ﬂuo-
ride, 1 mM Na3VO4, and 1:100 protease/phosphatase inhibitor
cocktails (Sigma). Crude lysates were centrifuged at 13,000 rpm for
10 min at 4 8C and the supernatants were collected for further
analysis. Protein concentrations were determined with the Bio-Rad
DC protein assay system. Lysates were boiled in the presence of 2.5%
b-mecaptoethanol, separated by denaturing SDS-PAGE, and trans-
ferred to 0.45-lm Optitran membranes (Schleicher & Schuell) in a
Bio-Rad transfer unit. Membranes were immunoblotted with the
appropriate primary antibody followed by horseradish peroxidase–
tagged secondary antibodies (Amersham Biosciences and Dako) and
detected with the SuperSignal West Pico System (Pierce).
Antibodies. FITC-conjugated goat anti-mouse IgM, rat IgG2aj
anti-mouse IgD (clone 11–26), rat IgG1j anti-mouse kappa (clone
187.1), rat IgG2bj anti-mouse lambda (clone JC5–1); PE-conjugated
goat anti-mouse IgG; un-conjugated goat anti-mouse kappa and anti-
mouse lambda were purchased from Southern Biotech. APC-
conjugated rat IgG2aj anti-mouse CD19 (clone 6D5), PE-conjugated
mouse IgG2aj anti-LMP1 (clone S12), un-conjugated mouse IgG2a
anti-Rb (clone 2), and anti-Cdk2 (clone 55) were purchased from BD
Bioscience. PE-conjugated rat IgG2aj anti-mouse CD5 (clone 53–7.3)
was purchased from eBioscience. Rat anti-LMP1 (clones 8G3, 1G6,
7E10, and 7G8) was purchased from Ascenion. Rabbit anti-pAkt
(Ser473), anti-pGSK3a/b (Ser21/9), anti-pStat3 (Tyr705), anti-pStat6
(Tyr641), anti-pmTOR (Ser2448), anti-Stat6, anti-Akt, anti-FoxO1,
and anti-p27 were purchased from Cell Signaling. Rabbit anti-Stat3
(H-190), anti-IjBa (C-21), and goat anti-b actin (I-19) were purchased
from Santa Cruz Biotechnology. Mouse IgG1j anti-GSK3 was
purchased from Upstate Biotechnology. Rabbit anti-pRb (Thr373)
was purchased from EMD Biosciences.
Supporting Information
Figure S1. Lymphomas Are Clonal by j Light Chain Rearrangement
PCR analysis of total spleen genomic DNA for the mouse j locus.
Primers were designed to amplify all V-J rearrangements, including
VJ1, VJ2, VJ4, and VJ5. Speciﬁc PCR products for the four
rearrangements corresponding to the calculated sizes are indicated
with arrows. Bands of other sizes are due to non-speciﬁc products. If a
tumor was present in the background of normal spleen cells, a single
band appears brighter than all the other speciﬁc bands. Wild-type
and LMP1 transgenic lymphocytes are positive for all four V-J
rearrangements and serve as positive controls. Clonality is deter-
mined by the appearance of a predominant band at the correct size
for a single V-J rearrangement.
Found at doi:10.1371/journal.ppat.0030166.sg001 (739 KB PDF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
ber for the EBV genome sequence is AJ507799. The gene identiﬁer
for LMP1 is BNLF1.
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